1
|
Grangeon L, Charbonnier C, Zarea A, Rousseau S, Rovelet-Lecrux A, Bendetowicz D, Lemaitre M, Malrain C, Quillard-Muraine M, Cassinari K, Maltete D, Pariente J, Moreaud O, Magnin E, Cretin B, Mackowiak MA, Sillaire AR, Vercelletto M, Dionet E, Felician O, Rod-Olivieri P, Thomas-Antérion C, Godeneche G, Sauvée M, Cartz-Piver L, Le Ber I, Chauvire V, Jonveaux T, Balageas AC, Laquerriere A, Duyckaerts C, Vital A, de Paula AM, Meyronet D, Guyant-Marechal L, Hannequin D, Tournier-Lasserve E, Campion D, Nicolas G, Wallon D. Phenotype and imaging features associated with APP duplications. Alzheimers Res Ther 2023; 15:93. [PMID: 37170141 PMCID: PMC10173644 DOI: 10.1186/s13195-023-01172-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 01/18/2023] [Indexed: 05/13/2023]
Abstract
BACKGROUND APP duplication is a rare genetic cause of Alzheimer disease and cerebral amyloid angiopathy (CAA). We aimed to evaluate the phenotypes of APP duplications carriers. METHODS Clinical, radiological, and neuropathological features of 43 APP duplication carriers from 24 French families were retrospectively analyzed, and MRI features and cerebrospinal fluid (CSF) biomarkers were compared to 40 APP-negative CAA controls. RESULTS Major neurocognitive disorders were found in 90.2% symptomatic APP duplication carriers, with prominent behavioral impairment in 9.7%. Symptomatic intracerebral hemorrhages were reported in 29.2% and seizures in 51.2%. CSF Aβ42 levels were abnormal in 18/19 patients and 14/19 patients fulfilled MRI radiological criteria for CAA, while only 5 displayed no hemorrhagic features. We found no correlation between CAA radiological signs and duplication size. Compared to CAA controls, APP duplication carriers showed less disseminated cortical superficial siderosis (0% vs 37.5%, p = 0.004 adjusted for the delay between symptoms onset and MRI). Deep microbleeds were found in two APP duplication carriers. In addition to neurofibrillary tangles and senile plaques, CAA was diffuse and severe with thickening of leptomeningeal vessels in all 9 autopsies. Lewy bodies were found in substantia nigra, locus coeruleus, and cortical structures of 2/9 patients, and one presented vascular amyloid deposits in basal ganglia. DISCUSSION Phenotypes associated with APP duplications were heterogeneous with different clinical presentations including dementia, hemorrhage, and seizure and different radiological presentations, even within families. No apparent correlation with duplication size was found. Amyloid burden was severe and widely extended to cerebral vessels as suggested by hemorrhagic features on MRI and neuropathological data, making APP duplication an interesting model of CAA.
Collapse
Affiliation(s)
- Lou Grangeon
- Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.
- Department of Neurology, Rouen University Hospital, Rouen Cedex, 76031, France.
| | - Camille Charbonnier
- Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - Aline Zarea
- Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - Stephane Rousseau
- Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - Anne Rovelet-Lecrux
- Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - David Bendetowicz
- Neurology Department, Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS and APHP, Hôpital de la Pitié-Salpétrière APHP, Paris, France
| | - Marion Lemaitre
- Geriatric department, Seclin-Carvin Hospital, Seclin, France
| | - Cécile Malrain
- Department of Neurology, Rennes Hospital, Rennes, France
| | | | - Kevin Cassinari
- Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - David Maltete
- Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - Jeremie Pariente
- Neurology Department, Toulouse University Hospital and Toulouse NeuroImaging Center (ToNIC) INSERM-Univeristy of Toulouse Paul Sabatier, Toulouse, France
| | - Olivier Moreaud
- Department of Neurology, Grenoble Hospital, Grenoble, France
| | - Eloi Magnin
- Department of Neurology, Besancon Hospital, Besancon, France
| | - Benjamin Cretin
- Department of Neurology, Hautepierre Hospital, Strasbourg, France
| | | | | | | | - Elsa Dionet
- Department of Neurology, Clermont-Ferrand Hospital, Clermont-Ferrand, France
| | - Olivier Felician
- APHM, Service de Neurologie et Neuropsychologie, CHU Timone, Marseille, France
- Aix Marseille Univ, INSERM, INS, Inst Neurosci Syst, Marseille, France
| | | | | | - Gaelle Godeneche
- Department of Neurology, La Rochelle Hospital, La Rochelle, France
| | - Mathilde Sauvée
- Department of Neurology, Grenoble Hospital, Grenoble, France
| | - Leslie Cartz-Piver
- Centre Mémoire Ressources et Recherche (CMRR), Limoges University Hospital, Limoges, France
| | - Isabelle Le Ber
- Neurology Department, Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS and APHP, Hôpital de la Pitié-Salpétrière APHP, Paris, France
| | - Valérie Chauvire
- Department of Neurology, Angers University Hospital, Angers, France
| | - Therèse Jonveaux
- Department of Neurology, Nancy University Hospital, Nancy, France
| | | | - Annie Laquerriere
- Department of Neuropathology, F 76000, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France
| | - Charles Duyckaerts
- Sorbonne Unviersité, INSERM, CNRS U1127, ICM and Laboratoire de Neuropathologie R. Escourolle, Hospital Pitie-Salpêtrière, Paris, France
| | - Anne Vital
- Department of Pathology, University Hospital, Bordeaux, France
| | | | - David Meyronet
- Department of Pathology, Hopital Civil University Hospital, Lyon, France
| | - Lucie Guyant-Marechal
- Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - Didier Hannequin
- Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - Elisabeth Tournier-Lasserve
- AP-HP, Groupe Hospitalier Saint-Louis Lariboisière-Fernand-Widal, Service de Génétique Moléculaire Neurovasculaire, INSERM UMR 1141, NeuroDiderot, Université de Paris, Paris, France
| | - Dominique Campion
- Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - Gaël Nicolas
- Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| | - David Wallon
- Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France
| |
Collapse
|
2
|
Boscher E, Husson T, Quenez O, Laquerrière A, Marguet F, Cassinari K, Wallon D, Martinaud O, Charbonnier C, Nicolas G, Deleuze JF, Boland A, Lathrop M, Frébourg T, Campion D, Hébert SS, Rovelet-Lecrux A. Copy Number Variants in miR-138 as a Potential Risk Factor for Early-Onset Alzheimer's Disease. J Alzheimers Dis 2020; 68:1243-1255. [PMID: 30909216 DOI: 10.3233/jad-180940] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Early-onset Alzheimer's disease (EOAD) accounts for 5-10% of all AD cases, with a heritability ranging between 92% to 100%. With the exception of rare mutations in APP, PSEN1, and PSEN2 genes causing autosomal dominant EOAD, little is known about the genetic factors underlying most of the EOAD cases. In this study, we hypothesized that copy number variations (CNVs) in microRNA (miR) genes could contribute to risk for EOAD. miRs are short non-coding RNAs previously implicated in the regulation of AD-related genes and phenotypes. Using whole exome sequencing, we screened a series of 546 EOAD patients negative for autosomal dominant EOAD mutations and 597 controls. We identified 86 CNVs in miR genes of which 31 were exclusive to EOAD cases, including a duplication of the MIR138-2 locus. In functional studies in human cultured cells, we could demonstrate that miR-138 overexpression leads to higher Aβ production as well as tau phosphorylation, both implicated in AD pathophysiology. These changes were mediated in part by GSK-3β and FERMT2, a potential risk factor for AD. Additional disease-related genes were also prone to miR-138 regulation including APP and BACE1. This study suggests that increased gene dosage of MIR138-2 could contribute to risk for EOAD by regulating different biological pathways implicated in amyloid and tau metabolism. Additional studies are now required to better understand the role of miR-CNVs in EOAD.
Collapse
Affiliation(s)
- Emmanuelle Boscher
- Centre de recherche du CHU de Québec-Université Laval, CHUL, Axe Neurosciences, Québec, Canada.,Faculté de médecine, Département de psychiatrie et de neurosciences, Université Laval, Québec, Canada
| | - Thomas Husson
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Olivier Quenez
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Annie Laquerrière
- Department of Pathology, Normandie Univ, UNIROUEN, Rouen University Hospital, Rouen, France
| | - Florent Marguet
- Department of Pathology, Normandie Univ, UNIROUEN, Rouen University Hospital, Rouen, France
| | - Kevin Cassinari
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - David Wallon
- Department of Neurology and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Olivier Martinaud
- Normandie Univ, UNICAEN, EPHE, INSERM, U1077, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, Caen, France
| | - Camille Charbonnier
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Gaël Nicolas
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Jean-François Deleuze
- Centre National de recherche en Génomique Humaine, Institut de Génomique, CEA, Evry, France
| | - Anne Boland
- Centre National de recherche en Génomique Humaine, Institut de Génomique, CEA, Evry, France
| | - Mark Lathrop
- McGill University and Génome Québec Innovation Centre, Montréal, Canada
| | - Thierry Frébourg
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | | | - Dominique Campion
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Sébastien S Hébert
- Centre de recherche du CHU de Québec-Université Laval, CHUL, Axe Neurosciences, Québec, Canada.,Faculté de médecine, Département de psychiatrie et de neurosciences, Université Laval, Québec, Canada
| | - Anne Rovelet-Lecrux
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| |
Collapse
|
3
|
Fontanilles M, Marguet F, Ruminy P, Basset C, Noel A, Beaussire L, Viennot M, Viailly PJ, Cassinari K, Chambon P, Richard D, Alexandru C, Tennevet I, Langlois O, Di Fiore F, Laquerrière A, Clatot F, Sarafan-Vasseur N. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma. Acta Neuropathol Commun 2020; 8:52. [PMID: 32303258 PMCID: PMC7165387 DOI: 10.1186/s40478-020-00917-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Accepted: 03/13/2020] [Indexed: 12/20/2022] Open
Abstract
Epidermal growth factor receptor (EGFR) amplification and EGFR variant III (EGFRvIII, deletion of exons 2-7) are of clinical interest for glioblastoma. The aim was to develop a digital PCR (dPCR)-based method using locked nucleic acid (LNA)-based hydrolysis probes, allowing the simultaneous detection of the EGFR amplification and EGFRvIII variant. Sixty-two patients were included. An exploratory cohort (n = 19) was used to develop the dPCR assay using three selected amplicons within the EGFR gene, targeting intron 1 (EGFR1), junction of exon 3 and intron 3 (EGFR2) and intron 22 (EGFR3). The copy number of EGFR was estimated by the relative quantification of EGFR1, EGFR2 and EGFR3 amplicon droplets compared to the droplets of a reference gene. EGFRvIII was identified by comparing the copy number of the EGFR2 amplicon to either the EGFR1 or EGFR3 amplicon. dPCR results were compared to fluorescence in situ hybridization (FISH) and next-generation sequencing for amplification; and to RT-PCR-based method for EGFRvIII. The dPCR assay was then tested in a validation cohort (n = 43). A total of 8/19 EGFR-amplified and 5/19 EGFRvIII-positive tumors were identified in the exploratory cohort. Compared to FISH, the EGFR3 dPCR assay detected all EGFR-amplified tumors (8/8, 100%) and had the highest concordance with the copy number estimation by NGS. The concordance between RT-PCR and dPCR was also 100% for detecting EGFRvIII using an absolute difference of 10.8 for the copy number between EGFR2 and EGFR3 probes. In the validation cohort, the sensitivity and specificity of dPCR using EGFR3 probes were 100% for the EGFR amplification detection compared to FISH (19/19). EGFRvIII was detected by dPCR in 8 EGFR-amplified patients and confirmed by RT-PCR. Compared to FISH, the EGFR2/EGFR3 dPCR assay was estimated with a one-half cost value. These results highlight that dPCR allowed the simultaneous detection of EGFR amplification and EGFRvIII for glioblastoma.
Collapse
|
4
|
Chatron N, Cassinari K, Quenez O, Baert-Desurmont S, Bardel C, Buisine MP, Calpena E, Capri Y, Corominas Galbany J, Diguet F, Edery P, Isidor B, Labalme A, Le Caignec C, Lévy J, Lecoquierre F, Lindenbaum P, Pichon O, Rollat-Farnier PA, Simonet T, Saugier-Veber P, Tabet AC, Toutain A, Wilkie AOM, Lesca G, Sanlaville D, Nicolas G, Schluth-Bolard C. Identification of mobile retrocopies during genetic testing: Consequences for routine diagnosis. Hum Mutat 2019; 40:1993-2000. [PMID: 31230393 DOI: 10.1002/humu.23845] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 05/29/2019] [Accepted: 06/17/2019] [Indexed: 12/24/2022]
Abstract
Human retrocopies, that is messenger RNA transcripts benefitting from the long interspersed element 1 machinery for retrotransposition, may have specific consequences for genomic testing. Next genetration sequencing (NGS) techniques allow the detection of such mobile elements but they may be misinterpreted as genomic duplications or be totally overlooked. We report eight observations of retrocopies detected during diagnostic NGS analyses of targeted gene panels, exome, or genome sequencing. For seven cases, while an exons-only copy number gain was called, read alignment inspection revealed a depth of coverage shift at every exon-intron junction where indels were also systematically called. Moreover, aberrant chimeric read pairs spanned entire introns or were paired with another locus for terminal exons. The 8th retrocopy was present in the reference genome and thus showed a normal NGS profile. We emphasize the existence of retrocopies and strategies to accurately detect them at a glance during genetic testing and discuss pitfalls for genetic testing.
Collapse
Affiliation(s)
- Nicolas Chatron
- Genetics Department, Hospices Civils de Lyon, Lyon, France.,GENDEV Team, CRNL, INSERM U1028, CNRS UMR5292, UCBL1, Lyon, France
| | - Kevin Cassinari
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Olivier Quenez
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Stéphanie Baert-Desurmont
- Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Claire Bardel
- Bioinformatics group of the Lyon University Hospital NGS facility, Groupement Hospitalier Est, Lyon, France.,Biostatistics and Bioinformatics Department, HCL, Lyon, France
| | - Marie-Pierre Buisine
- Department of Biochemistry and Molecular Biology, JPA Research Center, Inserm UMR-S 1172, Lille University, Lille University Hospital, Lille, France
| | - Eduardo Calpena
- Clinical Genetics Group, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Yline Capri
- Genetics Department, Clinical Genetics Unit, Hôpital Universitaire Robert Debré, Paris, France
| | | | - Flavie Diguet
- Genetics Department, Hospices Civils de Lyon, Lyon, France.,GENDEV Team, CRNL, INSERM U1028, CNRS UMR5292, UCBL1, Lyon, France
| | - Patrick Edery
- Genetics Department, Hospices Civils de Lyon, Lyon, France.,GENDEV Team, CRNL, INSERM U1028, CNRS UMR5292, UCBL1, Lyon, France
| | | | - Audrey Labalme
- Genetics Department, Hospices Civils de Lyon, Lyon, France
| | - Cedric Le Caignec
- Genetics Department, CHU Nantes, Nantes, France.,INSERM UMR_S915, Institut du thorax, Nantes University, Nantes, France
| | - Jonathan Lévy
- Genetics Department, Cytogenetics Unit, Hôpital Universitaire Robert Debré, Paris, France
| | - François Lecoquierre
- Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Pierre Lindenbaum
- INSERM, UMR_S1087, Institut du thorax, Nantes, France.,CNRS, UMR 6291, Nantes, France
| | | | - Pierre-Antoine Rollat-Farnier
- Genetics Department, Hospices Civils de Lyon, Lyon, France.,Bioinformatics group of the Lyon University Hospital NGS facility, Groupement Hospitalier Est, Lyon, France
| | - Thomas Simonet
- Cellular Biotechnology Center, Hospices Civils de Lyon, Lyon, France.,Nerve-Muscle Interactions Team, Institut NeuroMyoGène CNRS UMR 5310-INSERM U1217-Université Claude Bernard Lyon 1, Lyon, France
| | - Pascale Saugier-Veber
- Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Anne-Claude Tabet
- Genetics Department, Cytogenetics Unit, Hôpital Universitaire Robert Debré, Paris, France.,Neuroscience Department, Human Genetics and Cognitive Function Unit, Institut Pasteur, Paris, France
| | - Annick Toutain
- Genetics Department, Hôpital Bretonneau, CHU, Tours, France.,UMR 1253, iBrain, Tours University, Inserm, Tours, France
| | - Andrew O M Wilkie
- Clinical Genetics Group, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Gaetan Lesca
- Genetics Department, Hospices Civils de Lyon, Lyon, France.,GENDEV Team, CRNL, INSERM U1028, CNRS UMR5292, UCBL1, Lyon, France
| | - Damien Sanlaville
- Genetics Department, Hospices Civils de Lyon, Lyon, France.,GENDEV Team, CRNL, INSERM U1028, CNRS UMR5292, UCBL1, Lyon, France
| | - Gaël Nicolas
- Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Caroline Schluth-Bolard
- Genetics Department, Hospices Civils de Lyon, Lyon, France.,GENDEV Team, CRNL, INSERM U1028, CNRS UMR5292, UCBL1, Lyon, France
| |
Collapse
|
5
|
Collet G, Parodi N, Cassinari K, Neviere Z, Cohen F, Gasnier C, Brahimi A, Lecoquierre F, Thery JC, Tennevet I, Lacaze E, Berthet P, Frebourg T. Cost-effectiveness evaluation of pre-counseling telephone interviews before face-to-face genetic counseling in cancer genetics. Fam Cancer 2019; 17:451-457. [PMID: 29080081 DOI: 10.1007/s10689-017-0049-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
One of the main challenges in cancer genetics is responding to the exponential demand for genetic counseling, especially in patients with breast and/or ovarian cancer. To address this demand, we have set up a new procedure, based on pre-genetic counseling telephone interviews (PTI) followed by routing of patients: D1, a PTI is scheduled within 14 days; D7-D14, genetic counselors perform a 20 min PTI in order to establish a pre-genetic counseling file, by collecting personal and family medical history via a structured questionnaire and; D10-17, routing: pre-genetic counseling appointment files are analyzed by a cancer geneticist with 3 possible conclusions: (a) priority face-to-face genetic counseling (FTFGC) appointment with a cancer geneticist, if the genetic test results have an immediate therapeutic impact; (b) non-priority FTFGC with a genetic counselor, or (c) no FTFGC required or substitution by a more appropriate index case. In the context of breast and/or ovarian cancer, 1012 patients received PTIs, 39.1% of which did not lead to FTFGC. The mean delay for non-priority FTFGC was maintained at 18 weeks and priority FTFGC appointments were guaranteed within 8 weeks. The required resources for 1012 patients was estimated at 0.12 FTE secretaries, 0.62 FTE genetic counselors and 0.08 FTE cancer geneticists and the procedure was shown to be cost-effective. This new procedure allows the suppression of up to 1/3 of appointments, guarantees priority for appointments with therapeutic impact and optimizes the interaction and breakdown of tasks between genetic counselors and cancer geneticists.
Collapse
Affiliation(s)
- Gaëlle Collet
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
| | - Nathalie Parodi
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
| | - Kevin Cassinari
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
| | - Zoe Neviere
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
- Department of Genetics, Comprehensive Cancer Centre François Baclesse, Normandy Centre for Genomic and Personalized Medicine, 14000, Caen, France
| | - Fanny Cohen
- Department of Genetics, Comprehensive Cancer Centre François Baclesse, Normandy Centre for Genomic and Personalized Medicine, 14000, Caen, France
| | - Céline Gasnier
- Department of Genetics, Comprehensive Cancer Centre François Baclesse, Normandy Centre for Genomic and Personalized Medicine, 14000, Caen, France
| | - Afane Brahimi
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
| | - François Lecoquierre
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
| | - Jean-Christophe Thery
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
- Department of Oncology, Comprehensive Cancer Centre Henri Becquerel, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
| | - Isabelle Tennevet
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
- Department of Oncology, Comprehensive Cancer Centre Henri Becquerel, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France
| | - Elodie Lacaze
- Department of Genetics, Le Havre General Hospital, Normandy Centre for Genomic and Personalized Medicine, 76600, Le Havre, France
| | - Pascaline Berthet
- Department of Genetics, Comprehensive Cancer Centre François Baclesse, Normandy Centre for Genomic and Personalized Medicine, 14000, Caen, France
| | - Thierry Frebourg
- Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, 76000, Rouen, France.
- Department of Genetics, Rouen University Hospital, 22 boulevard Gambetta, 76183, Rouen Cedex 1, France.
| |
Collapse
|
6
|
Faivre JC, Agopiantz M, Loeb E, Cassinari K, Wack M, Catoire P, Braun M, Thilly N, Coudane H. [Evaluation of the theoretical teaching of postgraduate medical students in France]. Rev Med Interne 2015; 36:579-87. [PMID: 25980929 DOI: 10.1016/j.revmed.2015.02.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2014] [Revised: 12/13/2014] [Accepted: 02/07/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVES In France, medical students regularly complain about the shortcomings of their theoretical training and the necessity of its adaptation to better fit the needs of students. The goal was to evaluate the theoretical teaching practices in postgraduate medical studies by: 1) collecting data from medical students in different medical faculties in France; 2) comparing this data with expected practices when it is possible; 3) and proposing several lines of improvement. METHODS A survey of theoretical practices in the 3rd cycle of medical studies was conducted by self-administered questionnaires which were free of charge, anonymous, and administered electronically from July 3 to October 31, 2013 to all medical students in France. RESULTS National, inter-regional, regional and field internship educational content was absent in respectively 50.5%, 42.8%, 26.0% and 30.2% of cases. Medical students follow complementary training due to insufficient DES and/or DESC 2 training in 43.7% of cases or as part of a professional project in 54.9% of cases. The knowledge sought by medical students concerns the following crosscutting topics: career development (58.9%), practice management (50.7%), medical English (50.4%) and their specialty organization (49.9%). Fifty-four point one percent would like to be evaluated on their theoretical training on an annual basis. CONCLUSION The results of this first national survey give insights into the theoretical teaching conditions in postgraduate medical education in France and the aspirations of medical students.
Collapse
Affiliation(s)
- J-C Faivre
- Université de Lorraine, 54511 Vandœuvre-lès-Nancy, France; Département universitaire de radiothérapie, institut de cancérologie de Lorraine, 6, avenue de Bourgogne, CS 30519, 54511 Vandœuvre-lès-Nancy cedex, France; Inter syndicat national des internes, 75005 Paris, France.
| | - M Agopiantz
- Université de Lorraine, 54511 Vandœuvre-lès-Nancy, France; Inter syndicat national des internes, 75005 Paris, France; Département d'endocrinologie et de gynécologie médicale, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France
| | - E Loeb
- Inter syndicat national des internes, 75005 Paris, France; Université de Caen Basse-Normandie, 14000 Caen, France; Département de psychiatrie, CHU de Caen, 14000 Caen, France
| | - K Cassinari
- Inter syndicat national des internes, 75005 Paris, France; Université de Rouen, 76000 Rouen, France; CHU de Rouen, 76000 Rouen, France
| | - M Wack
- Université de Lorraine, 54511 Vandœuvre-lès-Nancy, France; Service d'épidémiologie et évaluation cliniques, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France
| | - P Catoire
- Université de Lille 2 droit et santé, 59000 Lille, France; Association nationale des étudiants en médecine de France, 75020 Paris, France
| | - M Braun
- Université de Lorraine, 54511 Vandœuvre-lès-Nancy, France; Département de neuroradiologie, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France
| | - N Thilly
- Université de Lorraine, 54511 Vandœuvre-lès-Nancy, France; Service d'épidémiologie et évaluation cliniques, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France
| | - H Coudane
- Université de Lorraine, 54511 Vandœuvre-lès-Nancy, France; Département de médecine légale, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France; Conférence des doyens des facultés de médecine, 75006 Paris, France
| |
Collapse
|